Literature DB >> 23198814

Comparison of the performance of HbA1c and fasting plasma glucose in identifying dysglycaemic status in Chinese high-risk subjects.

Ting-Ting Du1, Ping Yin, Jian-Hua Zhang, Dan Zhang, Wei Shi, Xue-Feng Yu.   

Abstract

The aim of the present study was to compare the performance of HbA1c and fasting plasma glucose (FPG) in identifying dysglycaemic status among Chinese participants. Fasting plasma glucose and HbA1c were measured in 2318 subjects with at least one risk factor for diabetes but without being previously diagnosed with diabetes. Using HbA1c to diagnose diabetes resulted in the same classification as FPG for 90.5% of the study participants, with 21.0% (n = 487) classified as having diabetes by both FPG and HbA1c and 69.5% (n = 1610) classified as not having diabetes by both FPG and HbA1c. The kappa (κ) coefficient of the FPG criterion with the HbA1c criterion for diabetes was 0.75 (95% confidence interval (CI) 0.72-0.78). The overlap index regarding diabetes diagnosed by FPG or HbA1c was 68.8%. Of 1610 subjects with FPG < 126 mg/dL and HbA1c < 6.5%, 220 (13.7%) had FPG ≥ 100 mg/dL and HbA1c < 5.7%, whereas 277 (17.2%) had FPG < 100 mg/dL and HbA1c ≥ 5.7%. The κ coefficient of the FPG criterion with the HbA1c criterion for prediabetes was 0.30 (95% CI 0.25-0.35). The overlap index between subjects diagnosed as having prediabetes by FPG of 100-125 mg/dL (impaired fasting glucose (IFG)) or HbA1c of 5.7-6.4% (increased HbA1c (IGH)) was 35.9%. The HbA1c criterion demonstrates reasonable concordance with the FPG criterion for diabetes. Hence, HbA1c and FPG can be used for the diagnosis of diabetes. However, the IGH shows limited overlap with IFG for prediabetes. Introduction of the IGH criterion in addition to IFG for the screening of prediabetes could lead to the identification of more people with this condition.
© 2012 The Authors Clinical and Experimental Pharmacology and Physiology © 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23198814     DOI: 10.1111/1440-1681.12038

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

1.  Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: findings from a population-based cohort study.

Authors:  Prakash Deedwania; Kanan Patel; Gregg C Fonarow; Ravi V Desai; Yan Zhang; Margaret A Feller; Fernando Ovalle; Thomas E Love; Inmaculada B Aban; Marjan Mujib; Mustafa I Ahmed; Stefan D Anker; Ali Ahmed
Journal:  Int J Cardiol       Date:  2013-05-31       Impact factor: 4.164

2.  Increasing glycaemia is associated with a significant decline in HDL cholesterol in women with prediabetes in two national populations.

Authors:  Chaiwat Washirasaksiri; Weerachai Srivanichakorn; Ian F Godsland; Chayanis Kositamongkol; Suwat Chariyalertsak; Pattapong Kessomboon; Sawitri Assanangkornchai; Surasak Taneepanichskul; Nareemarn Neelapaichit; Pochamana Phisalprapa; Desmond G Johnston; Nick S Oliver; Wichai Aekplakorn
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

3.  HbA1c alone is a poor indicator of cardiometabolic risk in middle-aged subjects with pre-diabetes but is suitable for type 2 diabetes diagnosis: a cross-sectional study.

Authors:  Seán R Millar; Ivan J Perry; Catherine M Phillips
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

4.  The prevalence and determinants of undiagnosed and diagnosed type 2 diabetes in middle-aged irish adults.

Authors:  Jennifer M O Connor; Seán R Millar; Claire M Buckley; Patricia M Kearney; Ivan J Perry
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

5.  Development of a new risk score for incident type 2 diabetes using updated diagnostic criteria in middle-aged and older chinese.

Authors:  Xingwang Ye; Geng Zong; Xin Liu; Gang Liu; Wei Gan; Jingwen Zhu; Ling Lu; Liang Sun; Huaixing Li; Frank B Hu; Xu Lin
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.